WJ001

An uniquely designed covalent XPO1 inhibitor of rapid clearance with broad-spectrum antitumor activity. It can be used to treat a variety of hematological cancers and solid tumors in clinic.

WJ002

A small molecule EGFR inhibitor that effectively inhibits the Exon 20 insertion mutations. Preclinical data show that WJ002 maintains the activity of inhibiting common EGFR mutations such as T790M, and at the same time overcomes the insensitivity of the 3rd EGFR inhibitor to exon20 insertion mutations.

WJ003

An oral available small molecule Aurora A inhibitor. Aurora A inhibitors have a synthetic lethal effect with RB1 deletion or inactivation, and can be used to treat malignant tumors with RB1 deletion or inactivation such as small cell lung cancer and triple-negative breast cancer.

WJ004

An effective fourth-generation EGFR inhibitor. Preclinical data show that the drug has a good inhibitory activity against acquired EGFR mutations, including Del19/T790M/C797S and L858R/T790M/C797S that are insensitive to third-generation EGFR inhibitors, and shows high selectivity over wild-type EGFR.

WJ005

Undisclosed

WJ006

Undisclosed

WJ007

Undisclosed

WJ008

Undisclosed

WJ009

Undisclosed

WJ010

Undisclosed

WJ011

Undisclosed